Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences

Area of Science:

• Dermatology and Immunology
• Pharmacotherapy

Background:

• Psoriasis is a chronic inflammatory skin disease with no cure, often co-occurring with psoriatic arthritis.
• Current systemic treatments like methotrexate have significant toxicities and require close monitoring.
• Emerging research highlights the role of T-cell cytokines in psoriasis pathogenesis.

Purpose of the Study:

• To review current and emerging selective immunotherapies for psoriasis.
• To discuss systemic therapies and disease immunopathogenesis.
• To highlight targeted approaches for immune modulation.

Main Methods:

• Literature review of scientific publications.
• Analysis of clinical studies and experiences.
• Synthesis of data on immunopathogenesis and treatment.

Main Results:

• Selective immunotherapies and biological agents show promise in treating psoriasis and psoriatic arthritis.
• These agents target specific immune responses, potentially reducing side effects.
• Clinical evidence supports the efficacy of novel immunomodulatory drugs.

Conclusions:

• Targeting cell-mediated immune reactions and inflammatory cytokines is key for modern psoriasis pharmacotherapy.
• Selective immunotherapies offer a less toxic alternative to traditional systemic treatments.
• Improved quality of life for psoriatic patients is a primary goal of these advanced therapies.